natgillin/translations-raw huggingface dataset:
The following table provides the frequency and severity of the ADRs based on results from REVEL, a phase 3 study in adult patients with NSCLC randomised to treatment with ramucirumab in combination with docetaxel or placebo plus docetaxel.
V naslednji tabeli sta navedeni pogostnost in resnost neželenih učinkov na podlagi rezultatov iz študije REVEL, študije III. faze pri odraslih bolnikih z NSCLC, ki so bili randomizirani v skupino za zdravljenje z ramucirumabom v kombinaciji z docetakselom ali pa v skupino za zdravljenje s placebom in docetakselom.
The following table shows an overview of the ADRs observed in the five clinical studies categorized according the MedDRA System Organ Class (SOC), Preferred Term Level (PT) and frequency.
Spodnja preglednica prikazuje pregled neželenih učinkov zdravila (ADR), o katerih so poročali v petih študijah, glede na MedDRA klasifikacijo organskih sistemov (System Organ Class - SOC), priporočenih izrazov in pogostnost.
The following table shows the percentage of subjects initially seronegative for rotavirus (IgA antibody titres < 20 U/ml) (by ELISA) with serum anti-rotavirus IgA antibody titers 20U/ml one to two months after the second dose of vaccine or placebo as observed in different studies with Rotarix lyophilised formulation.
V spodnji preglednici so prikazani odstotki oseb, ki so bile predhodno seronegativne na rotavirus (titri IgA protiteles < 20 e/ml) (ELISA), pri katerih je bil en ali dva meseca po aplikaciji drugega odmerka cepiva ali placeba v različnih študijah liofilizirane oblike cepiva Rotarix dosežen titer serumskih protirotavirusnih IgA protiteles  20 e./ml.
The following table shows the percentage of subjects initially seronegative for rotavirus (IgA antibody titres < 20 U/ml) (by ELISA) with serum anti-rotavirus IgA antibody titers 20U/ml one to two months after the second dose of vaccine or placebo as observed in different studies with Rotarix lyophilised formulation.
V spodnji preglednici so prikazani odstotki oseb, ki so bile predhodno seronegativne na rotavirus (titri IgA protiteles <20 e/ml) (ELISA), pri katerih je bil en ali dva meseca po aplikaciji drugega odmerka cepiva ali placeba v različnih študijah liofilizirane oblike cepiva Rotarix dosežen titer serumskih protirotavirusnih IgA protiteles  20 e./ml.
The following table shows the rates of the composite NPS adverse event primary endpoint by treatment group and the risk differences (RDs) (95% CI) vs placebo in the non-psychiatric cohort.
Naslednja preglednica prikazuje deleže neželenih dogodkov sestavljenega glavnega opazovanega dogodka NPS po zdravljenih skupinah in razlike v tveganjih (RD – risk differences) (95 % IZ) v primerjavi s placebom v nepsihiatrični kohorti.
The following table shows the size of spot-on applicator to be used according to the weight of the dog:
Naslednja tabela določa velikost kapalke, ki jo je potrebno uporabiti glede na težo psa:
The following table shows the time to complete wound closure from start of debridement.*
Naslednja preglednica prikazuje čas do popolnega zaprtja rane od začetka čiščenja.
The following table states the volume to be administered to deliver the prescribed dose:
V naslednji preglednici so navedeni volumni, ki se aplicirajo za zagotovitev predpisanega odmerka:
The following table summarises the adverse reactions reported in clinical studies and/or from post- marketing experience.
V naslednji preglednici so povzeti neželeni učinki, o katerih so poročali v kliničnih študijah in/ali v obdobju trženja.
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short- term clinical trials in adolescent patients.
Naslednja tabela vključuje neželene učinke, ki so jih poročali z višjo pogostnostjo pri mladostnikih (starih 13-17 let) kot pri odraslih bolnikih ali neželene učinke, ki so jih ugotovili samo v kratkoročnih kliničnih preskušanjih pri mladostnikih.
The following tables are derived from data gathered during the main studies in monotherapy for myelodysplastic syndromes and mantle cell lymphoma.
Naslednji preglednici vsebujeta podatke, zbrane med glavnimi študijami monoterapije mielodisplastičnih sindromov in limfoma plaščnih celic.
The following tables contain dosing guidelines for Kaletra oral solution based on body weight and BSA.
Naslednji tabeli vsebujeta smernice za odmerjanje zdravila Kaletra peroralna raztopina na osnovi telesne mase in indeksa telesne mase (ITM).
The following terms and frequencies are applied and presented by MedDRA System Organ Class: Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000).
Uporabljeni so naslednji izrazi in pogostnosti, ki so razvrščeni glede na organske sisteme po MedDRA: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do <1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000).
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from the available data).
Pri navajanju pogostnosti so uporabljeni naslednji izrazi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
The following terms and frequencies are applied: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000), and not known (cannot be estimated from the available data).
Pri navajanju pogostnosti neželenih učinkov so uporabljeni naslednji izrazi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The following terms are used to rank the undesirable effects by frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) including isolated reports.
Neželeni učinki so navedeni po pogostnosti na naslednji način: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), vključno s posameznimi primeri.
The following terms have been combined: a Abdominal pain, abdominal pain upper and abdominal pain lower b Oedema, oedema peripheral, eye oedema, localised oedema and face oedema c Dysgeusia, ageusia and hypogeusia d White cell count decreased, neutrophil count decreased and leukocyte count decreased e Decreased appetite and anorexia f Cardiac dysfunction, left ventricular dysfunction, cardiac failure and restrictive cardiomyopathy g Venous thromboembolic event, deep vein thrombosis, pulmonary embolism and thrombosis
Združeni so naslednji izrazi: a Bolečine v trebuhu, bolečine v zgornjem delu trebuha in bolečine v spodnjem delu trebuha b Edemi, periferni edemi, edemi oči, lokalizirani edemi in edem obraza c Dizgevzija, agevzija in hipogevzija d Zmanjšanje števila belih celic, zmanjšanje števila nevtrofilcev in zmanjšanje števila levkocitov e Zmanjšan apetit in neješčnost (anoreksija) f Disfunkcija srca, disfunkcija levega prekata, srčno popuščanje in restriktivna kardiomiopatija g Venski trombembolični dogodki, globoka venska tromboza, pljučna embolija in tromboza
The following terms have been combined: a Abdominal pain, abdominal pain upper and gastrointestinal pain b Oedema, oedema peripheral and eyelid oedema c The majority of these cases were Palmar-plantar erythrodysaesthesia syndrome d Venous thromboembolic events – includes Deep vein thrombosis, Pulmonary embolism and Thrombosis terms e The majority of these cases describe mucositis f Frequency is based on laboratory value tables from VEG110727 (N=240).
Združeni so naslednji izrazi: a Bolečine v trebuhu, bolečine v zgornjem delu trebuha in bolečine v prebavilih b Edemi, periferni edemi in edem vek c V večini primerov je šlo za sindrom palmarno-plantarne eritrodizestezije d Venski trombembolični dogodki - vključuje izraze globoka venska tromboza, pljučna embolija in tromboza e Večina teh primerov opisuje mukozitis f Pogostnost temelji na preglednicah laboratorijskih vrednosti iz VEG110727 (n = 240).
The following terms have been combined: a: Thrombocytopenia includes thrombocytopenia and decreased platelet count.
Naslednji izrazi so bili združeni: a: Trombocitopenija vključuje trombocitopenijo in zmanjšano število krvnih ploščic.
The following terms have been combined: a: Thrombocytopenia includes thrombocytopenia and platelet count decreased.
Naslednji izrazi so bili združeni: a: Trombocitopenija vključuje trombocitopenijo in zmanjšano število krvnih ploščic.
The following terms have been reported as adverse events during clinical trials, however, were reported at a similar or lower incidence in the MabThera arms compared to control arms: haematotoxicity, neutropenic infection, urinary tract infection, sensory disturbance, pyrexia.
Naslednji izrazi so bili med kliničnimi preskušanji zabeleženi kot neželeni učinki, a so imeli v skupinah, ki so prejemale zdravilo MabThera, podobno ali nižjo incidenco kot v kontrolnih skupinah: hematotoksičnost, nevtropenična okužba, okužba sečil, senzorična motnja, pireksija.
The following terms have been reported as adverse events during clinical trials, however, were reported at a similar or lower incidence in the MabThera-arms compared to control arms: haematotoxicity, neutropenic infection, urinary tract infection, sensory disturbance, pyrexia.
Naslednji izrazi so bili med kliničnimi preskušanji zabeleženi kot neželeni učinki, a so imeli v skupinah, ki so prejemale zdravilo MabThera, podobno ali nižjo incidenco kot v kontrolnih skupinah: hematotoksičnost, nevtropenična okužba, okužba sečil, senzorična motnja, pireksija.
The following terms were reported at a higher frequency in paediatric subjects when compared to adults: fatigue (very common), painful defaecation (very common), and dizziness (common).
O naslednjih izrazih so poročali pogosteje pri pediatričnih bolnikih kot pri odraslih: utrujenost (zelo pogosta), bolečine pri iztrebljanju (zelo pogoste) in omotica (pogosta).
The following treatment-related adverse reactions were reported in in adults clinical trials or through post-marketing surveillance in patients treated with peginterferon alfa-2b, including ViraferonPeg monotherapy or ViraferonPeg/ribavirin.
Med zdravljenjem so v času kliničnih preizkušanj ali v obdobju spremljanja zdravila na trgu pri odraslih bolnikih zdravljenih s peginterferonom alfa-2b, vključno z monoterapijo z zdravilom ViraferonPeg ali s kombinirano terapijo z zdravilom ViraferonPeg in ribavirinom poročali o naslednjih neželenih učinkih, povezanih z zdravljenjem.
The following undesirable effects cover adverse reactions from clinical trials
Sledeče neželene učinke so opazili pri kliničnih preskušanjih
The following undesirable effects cover adverse reactions from clinical trials
Sledeče neželene učinke so opazili pri kliničnih preskušanjih:
The following undesirable effects cover adverse reactions from clinical trials:
Sledeče neželene učinke so opazili pri kliničnih preskušanjih:
The following undesirable effects cover adverse reactions from post-marketing experience
Neželeni učinki, opaženi med trženjem zdravila
The following undesirable effects cover adverse reactions from post-marketing experience
Neželeni učinki, opaženi med trženjem zdravila:
The following undesirable effects cover adverse reactions from post-marketing experience
Neželeni učinki, opaženi v postmarketinških raziskavah
The following undesirable effects cover adverse reactions from post-marketing experience
Neželeni učinki, opaženi v postmarketinških raziskavah:
The following undesirable effects have been reported in clinical trials and/or post-marketing experience.
V kliničnih preskušanjih in/ali med uporabo po odobritvi zdravila so poročali o naslednjih neželenih učinkih.
The following very common side effects may be serious.
Naslednji zelo pogosti neželeni učinki so lahko resni.
The following warnings and precautions should be considered when ritonavir is used as an antiretroviral agent.
Če je ritonavir uporabljen kot protiretrovirusno zdravilo, je treba upoštevati naslednja opozorila in previdnostne ukrepe.
The following weight-adjusted dosing regimens are recommended for infants and children 1 year of age or older:
Priporočeno odmerjanje glede na telesno maso za dojenčke in otroke, stare 1 leto ali več, je:
The following were also considered: incidence rates higher than placebo, severity, seriousness and causality assessment of each individual case, consistency with Eslicarbazepine acetate pharmacology and data from open-label study phases and post-marketing safety data.
Upoštevali so tudi naslednje: večja incidenca kot pri placebu, izraženost, resnost ter vzročnost pri posameznih primerih, skladnost s farmakologijo eslikarbazepinacetata in podatki iz odprtih študij ter varnostni podatki iz obdobja trženja.
The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination.
Lamivudin-TP blokira nadaljnje nastajanje virusne DNA tako, da se vključi v verigo in s tem povzroči njeno terminacijo.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment which stops the treatment working properly.
Tvorba inhibitorjev (protiteles) je znan zaplet, ki se lahko pojavi med zdravljenjem ter ustavi ustrezno delovanje zdravljenja.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment, which stops the treatment working properly.
Tvorba inhibitorjev (protiteles) je znan zaplet, ki se lahko pojavi med zdravljenjem ter ustavi ustrezno delovanje zdravljenja.
The formation of inhibitors (neutralising antibodies) is a known complication that can occur during treatment, which stops the treatment working properly.
Nastanek inhibitorjev (nevtralizacijskih protiteles) je znan zaplet, ki se lahko pojavi med zdravljenjem ter ustavi ustrezno delovanje zdravljenja.
The formation of neutralising antibodies (inhibitors) against factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay.
Nastanek protiteles, ki nevtralizirajo faktor VIII (zaviralci), je znan zaplet pri zdravljenju posameznikov s hemofilijo A. Ti zaviralci so ponavadi imunoglobulini IgG, ki zavirajo prokoagulantno delovanje faktorja VIII, njihovo količino pa določamo v enotah Bethesda (B.e.) na ml plazme z uporabo prilagojenega testa.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay.
Nastanek nevtralizirajočih protiteles (inhibitorjev) proti faktorju VIII je znan zaplet pri zdravljenju bolnikov s hemofilijo A. Ti inhibitorji so običajno IgG imunoglobulini, ki delujejo tako, da zavirajo prokoagulacijsko delovanje faktorja VIII in so količinsko opredeljeni v enotah Bethesda (BE) na mililiter plazme z uporabo prilagojenega testa.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay.
Nastanek nevtralizirajočih protiteles (inhibitorjev) proti faktorju VIII je znan zaplet pri zdravljenju bolnikov s hemofilijo A. Ti inhibitorji so običajno IgG imunoglobulini, ki zavirajo prokoagulacijsko delovanje faktorja VIII in so količinsko opredeljeni v enotah Bethesda (BE) na mililiter plazme z uporabo prilagojenega testa.
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay.
Tvorba nevtralizirajočih protiteles (inhibitorjev) proti faktorju VIII je znan zaplet pri zdravljenju posameznikov s hemofilijo A. Ti inhibitorji so običajno IgG imunoglobulini, usmerjeni proti prokoagulacijski aktivnosti faktorja VIII, ki so količinsko opredeljeni v enotah Bethesda (BU - Bethesda Units) na ml plazme z uporabo prilagojene preiskave.
The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the FVIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma, using the modified assay.
Tvorba nevtralizirajočih protiteles (inhibitorjev) proti FVIII je znan zaplet pri zdravljenju posameznikov s hemofilijo A. Ti inhibitorji so običajno IgG imunoglobulini, usmerjeni proti prokoagulacijski aktivnosti FVIII, ki jih količinsko opredelimo v enotah Bethesda (Bethesda Units, BU) na ml plazme z uporabo prilagojene preiskave.
The formation of neutralising antibodies to factor VIII (inhibitors) is a known complication in the treatment of patients with haemophilia A. Your doctor may wish to carry out tests to monitor inhibitor development.
Nastanek nevtralizirajočih protiteles proti faktorju VIII (inhibitorji) je znan zaplet pri zdravljenju bolnikov s hemofilijo A. Zdravnik se lahko odloči za preiskave za spremljanje nastanka inhibitorjev.
The formation of some CYP450 enzymes is suppressed by increased levels of cytokines during chronic inflammation.
Zvišana koncentracija citokinov pri kroničnem vnetju zavira tvorbo nekaterih encimov CYP450.
The formation of some CYP450 enzymes is, however, suppressed by increased levels of cytokines during chronic inflammation.
Zvišana koncentracija citokinov pri kroničnem vnetju zavira tvorbo nekaterih encimov CYP450.
The formation of such antibodies is a known complication in the treatment of patients with haemophilia A. you have previously developed factor VIII inhibitors to a different product.
Nastajanje teh protiteles je znan zaplet pri zdravljenju bolnikov s hemofilijo A. so pri vas že kdaj nastali inhibitorji faktorja VIII na druga zdravila.
The formulation and dose to use depends on the animal, its bodyweight and the condition being treated.
Formulacija in višina odmerka sta odvisni od zdravljene živali, njene telesne mase in vrste bolezni, ki se zdravi.
The formulation does not contain a preservative.
Raztopina ne vsebuje sredstev za konzerviranje.
The formulation to use depends on the animal and the condition being treated.
Uporabljena formulacija je odvisna od vrste živali in bolezni, ki se zdravi.
The FORSTEO contains 28 days of medicine.
Zdravilo FORSTEO vsebuje zdravilo za 28 dni zdravljenja.
The FORSTEO is not recommended for use by the blind or visually impaired persons without the assistance of a person trained in the proper use of the device.
Injekcijskega peresnika FORSTEO ne priporočamo uporabljati slepim ali slabovidnim osebam, ki so brez pomoči ali osebe, usposobljene za pravilno uporabo medicinskega pripomočka.
The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with oral ondansetron 8 mg for 2 doses and oral dexamethasone 12 mg.
Režim zdravljenja s fosaprepitantom je vključeval 150 mg fosaprepitanta 1. dan v kombinaciji z ondansetronom 8 mg peroralno v 2 odmerkih in deksametazonom 12 mg peroralno.
The four principle pazopanib metabolites account for only 6 % of the exposure in plasma.
Štirje glavni presnovki pazopaniba predstavljajo le 6 % izpostavljenosti v plazmi.
The fourth (booster) dose is recommended between 11 and 15 months of age (see sections 4.4 and 5.1).
Cepljenje s četrtim (obnovitvenim) odmerkom je priporočljivo opraviti v starosti od 11. do 15. meseca (glejte poglavji 4.4 in 5.1).
The fourth study compared Multaq with amiodarone (another medicine used to prevent atrial fibrillation) in 504 patients and looked at the number of patients in whom atrial fibrillation came back or who had to stop treatment because it was causing side effects or not working.
V četrti študiji so pri 504 bolnikih zdravilo Multaq primerjali z amiodaronom (drugim zdravilom za preprečevanje atrijske fibrilacije) in ugotavljali število bolnikov, pri katerih se je atrijska fibrilacija ponovila ali pa so morali zaradi neželenih učinkov ali neučinkovitosti zdravila zdravljenje prekiniti.
The fourth study showed no evidence of a higher risk of fatal and non-fatal self- harm (HR of 0.88; 95% CI: 0.52-1.49) in patients prescribed varenicline compared to patients prescribed NRT.
V četrti študiji pri bolnikih, zdravljenih z vareniklinom, v primerjavi z bolniki, ki so prejemali NRT, niso ugotovili dokazov za povečano tveganje za samopoškodovanje s smrtnim izidom in brez smrtnega izida (HR 0,88; 95 % IZ: 0,52–1,49).
The fourth study showed that, after the second dose, the production of antibodies against mumps, and rubella was similar among babies who started vaccination at nine, 11 and 12 months.
Iz četrte študije je razvidno, da je pri dojenčkih po drugem odmerku tvorba protiteles proti mumpsu in rdečkam podobna, če so začeli s cepljenjem pri devetih, 11 ali 12 mesecih.
The fourth study was done in 201 patients with hepatitis C virus (genotypes 2 or 3) who did not respond to previous treatment with interferon or whose infections came back.
Četrto študijo so opravili na 201 bolniku z virusom hepatitisa C (genotipa 2 ali 3), pri katerem se okužba ni odzvala na predhodno zdravljenje z interferonom ali pa se je ponovno pojavila.
The fourth study was done in 302 patients with advanced neuroendocrine tumours of lung or gutorigin.
Četrto študijo so opravili s 302 bolnikoma z napredovalim nevroendokrinim tumorjem pljučnega ali črevesnega izvora.
The fourth week is transdermal patch-free starting on Day 22.
V četrtem tednu, ki se začne na 22. dan, transdermalnega obliža ne uporabljamo.
The fraction emitted as beta-particles is 3.6% (average energies are 0.445 MeV and
Delež energije, ki jo oddajajo v obliki delcev beta, je 3,6 % (povprečne energije so
The fraction of carbon dioxide gas, identified by its characteristic retention time, is introduced into mass spectrometer.
V masni spektrometer vnesemo frakcijo ogljikovega dioksida, ki jo določimo z zanj značilnim retencijskim časom.
The fraction of the dose extracted by the liver has been estimated to be 30-60%.
Del odmerka, ki se izloči skozi jetra, je ocenjen na 30–60 %.
The fraction unbound to proteins in plasma is 70-90%; insignificant binding of thiotepa to gamma globulin and minimal albumin binding (10-30%) has been reported.
Nevezane frakcije na beljakovine v plazmi je 70–90 %; poročali so o nepomembni vezavi tiotepe na gama globulin in o minimalni vezavi na albumin (10–30 %).
The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride.
Prosta osnovna oblika oksibutinina je farmakološko ekvivalentna oksibutininijevemu kloridu.
The free concentration of efavirenz required for 90 to 95% inhibition of wild type or zidovudine- resistant laboratory and clinical isolates in vitro ranged from 0.46 to 6.8 nM in lymphoblastoid cell lines, peripheral blood mononuclear cells (PBMCs) and macrophage/monocyte cultures.
Koncentracija prostega efavirenza, potrebna za 90 % do 95 % in vitro inhibicijo laboratorijskih in kliničnih izolatov divjega tipa ali tistih, ki so rezistentni na zidovudin, je bila v območju od 0,46 do 6,8 nM, in sicer v limfoblastoidnih celičnih linijah, perifernih krvnih enojedrnih celicah (PBMC) in v kulturah makrofagov/monocitov.